Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Earns “Positive” Rating from Cowen and Company

Cowen and Company reiterated their positive rating on shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in a research report report published on Thursday morning. They currently have a $50.00 target price on the specialty pharmaceutical company’s stock, up from their previous target price of $40.00.

Several other equities research analysts have also issued reports on the company. BidaskClub lowered Supernus Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday. Janney Montgomery Scott started coverage on Supernus Pharmaceuticals in a research note on Friday, July 14th. They set a neutral rating and a $47.00 price objective for the company. Stifel Nicolaus reissued a buy rating and set a $47.00 price objective (up previously from $36.00) on shares of Supernus Pharmaceuticals in a research note on Tuesday, July 18th. Piper Jaffray Companies lowered Supernus Pharmaceuticals from an overweight rating to a neutral rating and set a $46.00 price objective for the company. in a research note on Monday, July 17th. Finally, Jefferies Group LLC set a $35.00 price objective on Supernus Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, May 10th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Supernus Pharmaceuticals presently has an average rating of Buy and an average price target of $48.43.

Supernus Pharmaceuticals (NASDAQ SUPN) traded down 1.56% during midday trading on Thursday, reaching $41.05. The company’s stock had a trading volume of 661,571 shares. The firm has a market cap of $2.07 billion, a P/E ratio of 20.72 and a beta of 1.31. The firm has a 50 day moving average of $42.27 and a 200 day moving average of $33.33. Supernus Pharmaceuticals has a 52-week low of $17.25 and a 52-week high of $44.95.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.08. The company had revenue of $75.83 million during the quarter, compared to analysts’ expectations of $68.54 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. Analysts anticipate that Supernus Pharmaceuticals will post $1.00 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “[[title]]” was posted by [[site]] and is the property of of [[site]]. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at [[permalink]].

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 2,500 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $35.90, for a total transaction of $89,750.00. Following the completion of the sale, the vice president now owns 37,500 shares of the company’s stock, valued at $1,346,250. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 5,500 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $34.90, for a total value of $191,950.00. Following the sale, the vice president now directly owns 43,887 shares of the company’s stock, valued at approximately $1,531,656.30. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 24,291 shares of company stock valued at $962,766. Corporate insiders own 6.70% of the company’s stock.

A number of large investors have recently modified their holdings of SUPN. BlackRock Inc. raised its stake in shares of Supernus Pharmaceuticals by 156,173.3% in the first quarter. BlackRock Inc. now owns 6,696,310 shares of the specialty pharmaceutical company’s stock valued at $209,595,000 after buying an additional 6,692,025 shares during the period. Emerald Advisers Inc. PA purchased a new stake in shares of Supernus Pharmaceuticals during the second quarter valued at about $21,474,000. Emerald Mutual Fund Advisers Trust purchased a new stake in shares of Supernus Pharmaceuticals during the second quarter valued at about $17,553,000. Hodges Capital Management Inc. purchased a new stake in shares of Supernus Pharmaceuticals during the second quarter valued at about $17,220,000. Finally, Rice Hall James & Associates LLC raised its stake in shares of Supernus Pharmaceuticals by 24.5% in the second quarter. Rice Hall James & Associates LLC now owns 1,361,373 shares of the specialty pharmaceutical company’s stock valued at $58,675,000 after buying an additional 267,971 shares during the period. 91.23% of the stock is owned by hedge funds and other institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.